Premphase (Estrogen,Con/M-Progest Acet) Patent Expiration, LOE Window & CMS Spending

Premphase (Estrogen,Con/M-Progest Acet) by Pfizer: Off-Patent Genericized (AB Competition), 0 AB generics, $592K 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$592K
2024 Medicare Part D Spend$279K
2024 Medicaid Spend$313K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 10.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.